Literature DB >> 23406561

Do we still need chemotherapy for AIDS-associated Kaposi's sarcoma?

Alessia Dalla Pria1, Katy Hayward, Mark Bower.   

Abstract

The widespread introduction of effective combination antiretroviral therapy (cART) has had a major influence on the epidemiology and natural history of AIDS-associated Kaposi's sarcoma (AIDS-KS). cART has reduced the incidence of AIDS-KS, and it has been shown to be an effective treatment for early-stage KS. So with the widespread availability of cART, is systemic chemotherapy still required for AIDS-KS? Two indications appear to remain: advanced-stage AIDS-KS and patients who have progressive KS despite effective cART including immune reconstitution inflammatory syndrome KS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23406561     DOI: 10.1586/era.12.179

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  2 in total

1.  Severe Kaposi Sarcoma in an Urban Public Hospital.

Authors:  Shirin Elisha Kasturia; Clifford Gunthel; Cheng Zeng; Minh Ly Nguyen
Journal:  AIDS Res Hum Retroviruses       Date:  2017-01-31       Impact factor: 2.205

2.  Mannose-binding lectin concentrations in people living with HIV/AIDS infected by HHV-8.

Authors:  Viviane Martha Santos de Morais; Juliana Prado Gonçales; Georgea Gertrudes de Oliveira Mendes Cahú; Tania Regina Tozetto-Mendoza; Maria Rosângela Cunha Duarte Coêlho
Journal:  BMC Immunol       Date:  2019-01-03       Impact factor: 3.615

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.